✦ LIBER ✦

Ribonucleotide reductase subunit 2 (RRM2) predicts shorter survival in resected stage I–III non-small cell lung cancer (NSCLC) patients

✍ Scribed by Grossi, F.; Rijavec, E.; Dal Bello, M.G.; Savarino, G.; Sini, C.; Barletta, G.; Genova, C.; Truini, M.; Pfeffer, U.; Merlo, D.F.

Book ID: 119320855
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 47 KB
Volume: 77
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2012.05.038

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The immunohistochemical overexpression o

The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC)

✍ Lee, Jae Jin; Maeng, Chi Hoon; Baek, Seon Kyung; Kim, Gou Young; Yoo, Jee-Hong; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 301 KB

Long-term effect of HER-2/neu expression

Long-term effect of HER-2/neu expression on survival of stage I-IIIA non-small cell lung cancer (NSCLC) patients radically resected

✍ Selvaggi, G; Novello, S; Ferrari, G; Borasio, P; Mossetti, C; Ardissone, F; Laus 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 109 KB

Locoregional Recurrence Rate in Resected

Locoregional Recurrence Rate in Resected Stage III-N2 Non-small Cell Lung Cancers (NSCLC) with Nodal Downstaging Following Induction Chemotherapy

✍ A. Amini; S.H. Lin; A.M. Correa; S.G. Swisher; R. Komaki; K.M. Pisters; A. Tsao; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Pr3 ANITA: Phase III adjuvant vinorelbin

Pr3 ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I–III) non small cell lung cancer (NSCLC) patients (pts)

✍ Rosell, R.; de Lena, M.; Carpagnano, F.; Ramlau, R.; Gonzalez-Larriba, J.; Grodz 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 258 KB

The Effect of Pathological Response on S

The Effect of Pathological Response on Survival in Patients undergoing Trimodality Therapy for Surgically Staged N2 Non–small Cell Lung Cancer (NSCLC)

✍ G.A. Neuner; N.A. VanderWalde; O. Goulobeva; M. Suntharalingam; R.J. Battafarano 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Overexpression of eIF5A-2 is an adverse

Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non–small cell lung cancer patients

✍ Li-Ru He; Hong-Yun Zhao; Bin-Kui Li; Yan-Hui Liu; Meng-Zhong Liu; Xin-Yuan Guan; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 624 KB

## Abstract We have previously isolated an oncogene __EIF5A2__ (eukaryotic initiation factor 5A2) from a frequently amplified region at 3q of a primary ovarian cancer cell line, and demonstrated its impact on prognosis in human ovarian cancer. Amplification of chromosome 3q has also been detected f